Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2406109 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer.
Onco Targets Ther
November 2024
Department of Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Province, People's Republic of China.
In non-small cell lung cancer (NSCLC), Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in up to 30% of all cases, with the most prevalent mutations occurring in codons 12 and 13. The development of -targeted drugs like sotorasib and adagrasib has generated significant excitement in the clinical arena, offering new therapeutic options. Their potential for combination with other treatments broadens the scope for clinical exploration.
View Article and Find Full Text PDFDesign and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches.
Discov Oncol
October 2024
Protein Engineering Lab, School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Mutant KRAS promotes the proliferation, metastasis, and aggressiveness of various cancers including pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal adenocarcinoma (CRC) respectively. Mutant KRAS therapeutics are limited, while Sotorasib and Adagrasib were the only FDA-approved drugs for the treatment of KRAS mutated NSCLC. Chimeric antigen receptor (CAR) T-cell therapy has been emerged as an effective strategy against hematological malignancies and being extended towards solid cancers including PDAC.
View Article and Find Full Text PDFClinicopathological, molecular, and prognostic features of colorectal carcinomas with KRAS c.34G>T (p.G12C) mutation.
Cancer Sci
October 2024
Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts, USA.
Evidence indicates that combinations of anti-EGFR antibodies and KRAS p.G12C (c.34G>T) inhibitors can be an effective treatment strategy for advanced colorectal cancer.
View Article and Find Full Text PDFSotorasib in KRAS-Mutated Colorectal Cancer. Reply.
N Engl J Med
July 2024
Amgen, Thousand Oaks, CA.
Sotorasib in KRAS-Mutated Colorectal Cancer.
N Engl J Med
July 2024
Columbia University, New York, NY
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!